ANTX
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. (ANTX) has 17 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 10, 2026.
- Industry:Biotechnology
- CEO:Eric E. Easom
- Employees:22
- HQ:Menlo Park, CA, US
- IPO:2022-03-25
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$26K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$213.6M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Eizen Joshua MFirst filing | See Remarks | Sale | 5,945 | $25K | Jul 10 | SEC ↗ |
| Principal Accounting Officer | Sale | 265 | $1K | Jun 2 | SEC ↗ | |
Williams Sarah JoanneFirst filing | Principal Accounting Officer | Sale | 327 | $347 | Mar 5 | SEC ↗ |
Related companies
AN2 Therapeutics, Inc. is in the Healthcare sector.